Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 XenoGesis to Move Into BioCity Discovery Building | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances, Promotions & Moves

XenoGesis to Move Into BioCity Discovery Building

With grant funding from the Government’s Regional Growth Fund and the University of Derby Invest to Grow Program

By: Betsy Louda

, Contract Pharma

XenoGesis will be the next tenant to move into BioCity Nottingham’s state-of-the-art Discovery Building, with the support of grant funding from the Government’s Regional Growth Fund and the University of Derby Invest to Grow Program.

XenoGesis is an independent laboratory-based contract research organization specialized in preclinical drug metabolism and pharmacokinetics (DMPK), quantitative bioanalysis, in vitro pharmacology and modeling & simulation for human PK and dose prediction. 

The company will be taking 5,500ft2 on the first floor of the Discovery Building which was officially opened in June 2017. The new space will provide an 83% increase on the existing laboratories and offices that XenoGesis occupies in the Innovation Building. 

XenoGesis is a BioCity success story, starting out with a team of three the business has now grown to 25 employees, expanding its laboratory space and investing in state-of-the-art equipment.

Chief executive of BioCity, Glenn Crocker, said: “Since starting out at BioCity, XenoGesis has gone from strength to strength. This expansion is yet more evidence of the success of this great company and, I’m sure, the start of a new phase of growth. We are proud to have XenoGesis as an active member of the BioCity community and to be an investor in this high-quality business.”  

 

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters